ALT Altimmune Inc

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025.

Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at .

Participants who would like to join the call may register to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Company Contact:

Greg Weaver

Chief Financial Officer

Phone: 240-654-1450

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

Media Contact:

Danielle Cantey

Inizio Evoke, Biotech

Phone: 619-826-4657

This press release was published by a CLEAR® Verified individual.



EN
20/02/2025

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the...

Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first patient in the RESTORE Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol-Associated Liver Disease (ALD). Pemvidutide is a novel, investigational GLP-1/glucagon ...

July 9, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b ...

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up t...

June 26, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b...

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment o...

June 25, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Multiple Presentations at Upcoming American Diabet...

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions GAITHERSBURG, Md., June 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced an oral presentation and three poster presentations on pemvidutide at the American Diabetes Association’s (ADA) 85th Scientific Sessions, to be held in Chicago, IL from June 20-23, 2025. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under d...

June 13, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the...

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled the first subject in the RECLAIM Phase 2 trial evaluating the efficacy and safety of pemvidutide in subjects with Alcohol Use Disorder (AUD). Pemvidutide is a novel, investigational GLP-1/glucagon dual recep...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch